Trevena (NASDAQ:TRVN) Now Covered by StockNews.com

Investment analysts at StockNews.com began coverage on shares of Trevena (NASDAQ:TRVNGet Rating) in a research note issued on Friday. The firm set a “sell” rating on the biopharmaceutical company’s stock.

Separately, HC Wainwright cut their price objective on Trevena from $5.00 to $3.50 in a report on Thursday, May 12th.

TRVN stock opened at $0.46 on Friday. The company has a market capitalization of $76.14 million, a PE ratio of -1.31 and a beta of 2.44. Trevena has a 12-month low of $0.18 and a 12-month high of $2.00. The business’s fifty day moving average price is $0.33 and its 200 day moving average price is $0.46.

Trevena (NASDAQ:TRVNGet Rating) last posted its quarterly earnings data on Wednesday, May 11th. The biopharmaceutical company reported ($0.10) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.09) by ($0.01). The firm had revenue of $0.02 million during the quarter, compared to analysts’ expectations of $0.65 million. Trevena had a negative net margin of 7,771.74% and a negative return on equity of 82.39%. During the same quarter in the prior year, the firm posted ($0.06) EPS. Sell-side analysts expect that Trevena will post -0.37 EPS for the current fiscal year.

Hedge funds and other institutional investors have recently modified their holdings of the business. Geode Capital Management LLC increased its holdings in Trevena by 11.3% during the 3rd quarter. Geode Capital Management LLC now owns 3,028,595 shares of the biopharmaceutical company’s stock worth $3,725,000 after purchasing an additional 306,851 shares during the period. Renaissance Technologies LLC increased its holdings in Trevena by 90.8% during the 1st quarter. Renaissance Technologies LLC now owns 308,400 shares of the biopharmaceutical company’s stock worth $170,000 after purchasing an additional 146,800 shares during the period. Captrust Financial Advisors increased its holdings in Trevena by 10,526.3% during the 1st quarter. Captrust Financial Advisors now owns 201,900 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 200,000 shares during the period. Finally, GSA Capital Partners LLP purchased a new stake in Trevena during the 1st quarter worth about $471,000. Institutional investors own 21.20% of the company’s stock.

Trevena Company Profile (Get Rating)

Trevena, Inc, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders. Its lead product candidates include OLINVYK (Oliceridine) injection, a G protein biased mu-opioid receptor (MOR) ligand for the management of moderate-to-severe acute pain; TRV027 for the treatment of acute lung injury contributing to acute respiratory distress syndrome and abnormal blood clotting in patients with COVID-19; TRV250, a G protein biased delta-opioid receptor agonist for the treatment of acute migraine; TRV734, a small molecule G protein biased ligand of the MOR for the treatment of moderate-to-severe acute and chronic pain; and TRV045, a novel S1P modulator for managing chronic pain.

Featured Articles

Receive News & Ratings for Trevena Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Trevena and related companies with MarketBeat.com's FREE daily email newsletter.